Phase I trial of alpha-particle immunotherapy with 225Ac-lintuzumab and low-dose cytarabine in patients age 60 or older with untreated acute myeloid leukemia.

Conclusion: Fractionated-dose 225Ac-linutuzmab can be safely combined with LDAC and induce remission in older patients with untreated AML. A phase II trial of 225Ac-lintuzumab at 74 kBq/kg/fraction using hydroxyurea, if necessary, to lower peripheral blast counts prior to administration to determine response rate, PFS, and OS in this patient population is in progress. Research Support: Actinium Pharmaceuticals, Inc. provided 225Ac-lintuzumab and funded this trial. Objective ResponsesResponse18.5 kBq/kg/fraction (n=3)37 kBq/kg/fraction (n=6)55.5 kBq/kg/fraction (n=3)74 kBq/kg/fraction (n=6)All Dose Levels (n=18)CR01 (17%)1 (33%)02 (11%)CRp0001 (17%)1 (6%)CRi001 (33%)1 (17%)2 (11%)Overall Response01 (17%)2 (67%)2 (33%)5 (28%)

Source: Journal of Nuclear Medicine - May 24, 2017 Category: Nuclear Medicine Authors: Jurcic, J., Levy, M., Park, J., Ravandi, F., Perl, A., Pagel, J., Smith, B., Orozco, J., Estey, E., Kantarjian, H., Cicic, D., Scheinberg, D. Tags: Radiopharmaceutical Therapy- Radioimmunotherapy and Radioembolization Source Type: research